KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Amortization of Deferred Charges: 2012-2018

Historic Amortization of Deferred Charges for Halozyme Therapeutics (HALO) over the last 6 years, with Dec 2018 value amounting to -$455,000.

  • Halozyme Therapeutics' Amortization of Deferred Charges rose 26.26% to -$455,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $1.5 million, marking a year-over-year decrease of 12.27%. This contributed to the annual value of $1.5 million for FY2018, which is 12.27% down from last year.
  • According to the latest figures from Q4 2018, Halozyme Therapeutics' Amortization of Deferred Charges is -$455,000, which was down 250.17% from $303,000 recorded in Q3 2018.
  • Over the past 5 years, Halozyme Therapeutics' Amortization of Deferred Charges peaked at $3.7 million during Q3 2016, and registered a low of -$6.3 million during Q4 2016.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $462,500 (2017), whereas its average is $516,833.
  • The largest annual percentage gain for Halozyme Therapeutics' Amortization of Deferred Charges in the last 5 years was 998.84% (2016), contrasted with its biggest fall of 1,847.49% (2016).
  • Over the past 5 years, Halozyme Therapeutics' Amortization of Deferred Charges (Quarterly) stood at $415,000 in 2014, then decreased by 13.73% to $358,000 in 2015, then tumbled by 1,847.49% to -$6.3 million in 2016, then surged by 90.14% to -$617,000 in 2017, then increased by 26.26% to -$455,000 in 2018.
  • Its last three reported values are -$455,000 in Q4 2018, $303,000 for Q3 2018, and $345,000 during Q2 2018.